Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.

ABSTRACT:

Purpose

To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration.

Design

Nonrandomized clinical trial.

Methods

Ten patients with CNV received infusions of 5 mg/kg of bevacizumab. The primary efficacy outcome measure was change in visual acuity (VA; Early Treatment Diabetic Retinopathy Study letters read at 4 meters) at 24 weeks and secondary measures were changes from baseline in excess foveal thickness (center subfield thickness), area of fluorescein leakage, and area of CNV.

Results

Infusions were well tolerated and there were no ocular or systemic adverse events. At baseline, median VA was 25.5 letters

SUBMITTER: Nguyen QD 

PROVIDER: S-EPMC4868052 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature